Physician profile
Jasbir S Rangi
NPI 1578699104
$18,138.17
in general payments reported to CMS, 2019-2025
42 companies · $3,719 in 2025
The $3,719 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,719 · 2020: $1,327 · 2021: $1,564 · 2022: $2,438 · 2023: $2,735 · 2024: $3,638 · 2025: $3,719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,902 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,902.30 |
| Education | $188.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,346.34 | 2019-2025 | |
| Janssen Biotech, INC. | $1,800.90 | 2019-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,619.21 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $1,513.75 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Genzyme Corporation | $1,074.20 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $648.54 | 2021-2023 | |
| Pfizer INC. | $582.05 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $553.09 | 2019-2023 | Dificid |
| Qol Medical, LLC | $511.64 | 2019-2025 | Sucraid, Sucraid |
| Celgene Corporation | $479.68 | 2021-2024 | Zeposia |
| Romark Laboratories, Lc | $431.19 | 2019-2020 | |
| Gilead Sciences, INC. | $380.70 | 2019-2024 | |
| Madrigal Pharmaceuticals | $354.87 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $347.03 | 2024-2025 | Vowst, Zenpep |
| Ardelyx, INC. | $309.62 | 2024-2025 | Ibsrela |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $307.57 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $219.28 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $181.77 | 2019-2023 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $168.60 | 2023-2025 | Dupixent |
| Ferring Pharmaceuticals INC. | $154.38 | 2019-2024 | Rebyota |
| Organon LLC | $148.09 | 2022-2025 | Hadlima, Renflexis |
| Fresenius Kabi USA, LLC | $117.92 | 2023-2024 | Idacio |
| Biocon Biologics INC | $112.88 | 2025 | Yesintek |
| Braintree Laboratories, INC. | $112.80 | 2019-2022 | |
| Daiichi Sankyo INC. | $98.51 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $95.49 | 2019-2024 | Linzess |
| Redhill Biopharma INC. | $79.37 | 2020-2022 | |
| Exact Sciences Corporation | $72.36 | 2023 | Cologuard Collection Kit |
| Alnylam Pharmaceuticals INC. | $32.06 | 2021 | |
| Alfasigma USA, INC. | $30.95 | 2020 | |
| Boston Scientific Corporation | $30.58 | 2023 | Radial Jaw 4 |
| Alexion Pharmaceuticals, INC. | $25.66 | 2019 | |
| Janssen Pharmaceuticals, INC | $24.45 | 2025 | Tremfya |
| Albireo Pharma, INC. | $24.33 | 2024 | Bylvay |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.14 | 2023 | Cyltezo |
| Sandoz INC. | $21.84 | 2023 | Hyrimoz |
| Novo Nordisk INC | $20.82 | 2025 | Wegovy |
| Celltrion USA INC. | $19.89 | 2024 | Zymfentra |
| Shionogi INC | $17.88 | 2019 | |
| Amag Pharmaceuticals, INC. | $17.09 | 2019 | |
| Olympus America INC. | $15.07 | 2024 | Gastrointestinal Videoscope, Evis Exera III Colonovideoscope |
| Ethicon US, LLC | $13.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasbir Rangi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.